273 related articles for article (PubMed ID: 34392915)
21. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with Breast Cancer.
Ulaner GA; Vaz SC; Groheux D
PET Clin; 2024 Apr; 19(2):147-162. PubMed ID: 38177052
[TBL] [Abstract][Full Text] [Related]
22. Update on advances in molecular PET in urological oncology.
Kitajima K; Yamamoto S; Fukushima K; Minamimoto R; Kamai T; Jadvar H
Jpn J Radiol; 2016 Jul; 34(7):470-85. PubMed ID: 27222021
[TBL] [Abstract][Full Text] [Related]
23. Non-
Kalshetty A; Basu S
PET Clin; 2018 Apr; 13(2):239-248. PubMed ID: 29482752
[TBL] [Abstract][Full Text] [Related]
24. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
Goodman K; Abel MK; Lawhn-Heath C; Molina-Vega J; Jones EF; Mukhtar RA
Surg Oncol Clin N Am; 2022 Oct; 31(4):569-579. PubMed ID: 36243494
[No Abstract] [Full Text] [Related]
25. Newly-Developed Positron Emission Mammography (PEM) Device for the Detection of Small Breast Cancer.
Yanai A; Itoh M; Hirakawa H; Yanai K; Tashiro M; Harada R; Yoshikawa A; Yamamoto S; Ohuchi N; Ishida T
Tohoku J Exp Med; 2018 May; 245(1):13-19. PubMed ID: 29731479
[TBL] [Abstract][Full Text] [Related]
26. A Comparison of
Slouka D; Krcal J; Kostlivy T; Hrabacka P; Skalova A; Mirka H; Topolcan O; Kucera R
In Vivo; 2020; 34(4):2029-2032. PubMed ID: 32606177
[TBL] [Abstract][Full Text] [Related]
27. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
[TBL] [Abstract][Full Text] [Related]
28. [18F]FDG PET/CT in the staging of inflammatory breast cancer: A systematic review.
van Uden DJP; Prins MW; Siesling S; de Wilt JHW; Blanken-Peeters CFJM; Aarntzen EHJG
Crit Rev Oncol Hematol; 2020 Jul; 151():102943. PubMed ID: 32416347
[TBL] [Abstract][Full Text] [Related]
29. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
30. FDG PET Hybrid Imaging.
Becker J; Schwarzenböck SM; Krause BJ
Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
[TBL] [Abstract][Full Text] [Related]
31. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
32. Subtype-Guided
Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
[TBL] [Abstract][Full Text] [Related]
33. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
34. Whole-Body [
Berzaczy D; Fueger B; Hoeller C; Haug AR; Staudenherz A; Berzaczy G; Weber M; Mayerhoefer ME
Mol Imaging Biol; 2020 Jun; 22(3):739-744. PubMed ID: 31363965
[TBL] [Abstract][Full Text] [Related]
35. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
36. The impact of
Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
[TBL] [Abstract][Full Text] [Related]
37. PET in breast cancer.
Flanagan FL; Dehdashti F; Siegel BA
Semin Nucl Med; 1998 Oct; 28(4):290-302. PubMed ID: 9800236
[TBL] [Abstract][Full Text] [Related]
38. Application of PET Tracers in Molecular Imaging for Breast Cancer.
Boers J; de Vries EFJ; Glaudemans AWJM; Hospers GAP; Schröder CP
Curr Oncol Rep; 2020 Jul; 22(8):85. PubMed ID: 32627087
[TBL] [Abstract][Full Text] [Related]
39. 18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract][Full Text] [Related]
40. PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?
Suresh Malapure S; Das KJ; Kumar R
PET Clin; 2016 Jul; 11(3):297-303. PubMed ID: 27321033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
